Skip to main content

Advertisement

Fig. 4 | Cancer Cell International

Fig. 4

From: MLL2/KMT2D and MLL3/KMT2C expression correlates with disease progression and response to imatinib mesylate in chronic myeloid leukemia

Fig. 4

MLL2/KMT2D and MLL3/KMT2C expression in KCL22 cell lines resistant or sensitive to IM. a Expression of both genes was decreased in IM resistant KCL22R cells after treatment with either dasatinib or nilotinib compared to the untreated cells. Treatment with dasatinib or nilotinib in IM sensitive KCL22S cells, resulted in four and threefold increase in the expression of MLL2/KMT2D and MLL3/KMT2C, respectively. b KCL22S cells treated with either dasatinib or nilotinib showed an increase in the expression of p21 (CDKN1A) and a concomitant decrease of CDK2, CDK4 and Cyclin B1 in comparison to untreated KCL22S control. This difference in the expression was not observed in KCL22R cells after treatment with either TKI compounds. c Flow cytometry analysis of annexin-V and propidium iodide (PI) staining of apoptotic cells following dasatinib (10 nM), nilotinib (18 nM) and imatinib (10 μM) treatment or DMSO-treated control in KCL22S and KCL22R, showing percentage of apoptotic cells (annexin-V positive + PI positive + annexin-V and PI double positive cells). (**p < 0.01, ***p < 0.001 and ****p < 0.0001, ns: non-significant). d Percentage of viable cells following dasatinib (10 nM) nilotinib (18 nM) and imatinib (10 μM) treatment or DMSO-treated control in KCL22S and KCL22R (**p < 0.01 and ***p < 0.001, ns: non-significant)

Back to article page